Zirabev (bevacizumab) 400 mg, Pfizer, USA Order Zirabev (bevacizumab) 400 mg, Pfizer, USA. International medicine delivery within 4-5 days with storage conditions maintained. Payment on delivery. Order at +380996042415 via Viber or WhatsApp.

Delivery of medicines from abroad subject to temperature control, payment upon receipt.

Indications:

• Treatment of metastatic colorectal cancer:
• in combination with derivative-based chemotherapy fluoropyrimidines.
• Treatment of metastatic breast cancer
• first line of treatment in combination with paclitaxel;
• first line of treatment in combination with capecitabine (when treatment with other chemotherapy regimens, including taxanes or anthracyclines, is considered inappropriate). Patients who have received taxane- and anthracycline-based regimens in the adjuvant setting within the past 12 months should not be treated with Avastin® in combination with capecitabine.
• Treatment of unresectable advanced, metastatic or recurrent non-small cell lung cancer, excluding predominantly squamous cell lung cancer:
• first line of treatment in combination with chemotherapy based on platinum derivatives.
• Treatment of advanced and/or metastatic renal cell cancer:
• first line of therapy in combination with interferon alfa-2a.
• Treatment of advanced (stage III B, III C and IV according to the classification of the International Federation of Obstetrics and Gynecology (FIGO)) epithelial cancer of the ovaries, fallopian tube and primary peritoneal cancer in adult patients:
• as first-line therapy in combination with carboplatin and paclitaxel.
• Treatment of the first relapse of epithelial ovarian cancer, fallopian tube and primary peritoneal cancer, sensitive to treatment with platinum drugs:
• in combination with carboplatin and gemcitabine in adult patients who have not received prior therapy with bevacizumab or other vascular endothelial growth factor inhibitors or agents whose action is directed to the vascular endothelial growth factor receptor.
• Treatment of recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer resistant to drug treatment platinum:
• in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin in adult patients who have received no more than two previous chemotherapy regimens and have not received prior therapy with bevacizumab or other VEGF inhibitors or drugs that target the VEGF receptor.
• Treatment of persistent, recurrent or metastatic cervical cancer
• in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in adult patients who cannot receive platinum therapy.
•  
• ovastin, altuzan, oltuzan, avostin, ovostine